HNRNPG — Heterogeneous Nuclear Ribonucleoprotein G

HNRNPG — Heterogeneous Nuclear Ribonucleoprotein G

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">HNRNPG Protein</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>HNRNPG</td></tr>
<tr><td><strong>Full Name</strong></td><td>Heterogeneous Nuclear Ribonucleoprotein G</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>2p22.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3169](https://www.ncbi.nlm.nih.gov/gene/3169)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[605018](https://omim.org/entry/605018)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000197746](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197746)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y676](https://www.uniprot.org/uniprot/Q9Y676)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>hnRNP G family</td></tr>
<tr><td><strong>Protein Length</strong></td><td>497 amino acids</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Nucleus, cytoplasm</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy)</td></tr>
</table>
</div>

Overview

HNRNPG — Heterogeneous Nuclear Ribonucleoprotein G

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">HNRNPG Protein</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>HNRNPG</td></tr>
<tr><td><strong>Full Name</strong></td><td>Heterogeneous Nuclear Ribonucleoprotein G</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>2p22.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3169](https://www.ncbi.nlm.nih.gov/gene/3169)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[605018](https://omim.org/entry/605018)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000197746](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197746)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y676](https://www.uniprot.org/uniprot/Q9Y676)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>hnRNP G family</td></tr>
<tr><td><strong>Protein Length</strong></td><td>497 amino acids</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Nucleus, cytoplasm</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy)</td></tr>
</table>
</div>

Overview

HNRNPG (Heterogeneous Nuclear Ribonucleoprotein G) encodes an RNA-binding protein that plays critical roles in post-transcriptional gene regulation. As a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, HNRNPG contains RNA recognition motifs (RRMs) that enable it to bind specific RNA sequences and regulate alternative splicing, mRNA stability, transport, and translation[@hein2015][@chen2019]. The protein is ubiquitously expressed with particularly high levels in the brain, where it participates in neuronal development, synaptic function, and stress responses. Dysregulation of HNRNPG has been implicated in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and spinal muscular atrophy (SMA)[@liu2020][@wang2021].

The hnRNP family consists of over 20 abundant proteins that associate with pre-mRNA and mRNA to form ribonucleoprotein complexes. HNRNPG, also known as RBMX or RNA-binding motif protein on X chromosome, represents a unique member with specialized functions in RNA processing. Its role in regulating transcripts involved in neuronal survival, synaptic plasticity, and stress response makes it a significant player in neurodegenerative processes.

Gene Structure and Evolution

Genomic Organization

The HNRNPG gene is located on chromosome 2p22.2 and encodes a protein of 497 amino acids. The gene is evolutionarily conserved, with orthologs identified across vertebrates.

The gene structure includes:

• Multiple exons: Complex genomic organization
• Alternative splicing: Generates multiple transcript variants
• Promoter region: Contains regulatory elements for tissue-specific expression

Evolutionary Conservation

HNRNPG shows significant evolutionary conservation:

• Present in all vertebrates examined
• RRM domains highly conserved
• The RGG box (arginine-glycine-glycine) is characteristic of the family

Family Members

The hnRNP G family includes:

• HNRNPG (RBMX): The canonical member
• RBMXL1: Testis-specific variant
• RBMY: Y-chromosome copies

Protein Structure and Function

Domain Architecture

HNRNPG contains several functional domains:

Structural Features

The HNRNPG protein contains:

• RRM1: Major RNA-binding domain
• RRM2:辅助 RNA binding
• RGG domain: Mediates interactions with other proteins
• C-terminal region: Protein-protein interaction sites

Biological Functions

HNRNPG participates in multiple RNA-related processes[@dutta2015][@kamma2005]:

• Regulates inclusion/exclusion of exons
• Modulates splice site selection
• Influences tissue-specific splicing patterns

• Binds to specific mRNAs to regulate half-life
• Protects mRNAs from degradation
• Coordinates RNA turnover

• Facilitates mRNA trafficking to cellular compartments
• Involved in dendritic RNA transport in neurons

• Modulates translation efficiency
• Regulates ribosome loading onto mRNAs

Expression and Localization

Tissue Distribution

HNRNPG shows ubiquitous expression with high levels in:

High expression:

• Brain: Cerebral cortex, hippocampus, cerebellum
• Testis: Germ cells
• Spinal cord: Motor neurons

• Heart: Cardiac myocytes
• Liver: Hepatocytes
• Kidney: Tubular cells

Brain Expression

In the nervous system, HNRNPG is expressed in:

• Neurons: Throughout CNS and PNS
• Astrocytes: Glial cells
• Microglia: Immune cells
• Oligodendrocytes: Myelinating cells

Subcellular Localization

HNRNPG localizes to:

• Nucleus: Primary site of function
• Nucleolus: Some isoforms
• Cytoplasm: For transport and translation
• Stress granules: Under cellular stress

Role in Neurological Diseases

Amyotrophic Lateral Sclerosis (ALS)

HNRNPG is implicated in ALS pathogenesis[@liu2020][@geuens2016]:

1. RNA Processing Dysregulation

• Altered splicing patterns in ALS motor neurons
• Disrupted RNA processing of survival genes
• Contributes to motor neuron degeneration

• HNRNPG localizes to stress granules
• Abnormal stress granule dynamics in ALS
• Contributes to RNA metabolism defects

• Interacts with TDP-43 in stress granules
• Coordinates RNA metabolism with other RBPs
• May affect TDP-43 pathology

Frontotemporal Dementia (FTD)

HNRNPG contributes to FTD pathogenesis[@van2019][@martinez2017]:

1. RNA Metabolism Defects

• Altered RNA processing in FTD brains
• Dysregulated splicing of neuronal genes
• Contributes to neurodegeneration

• Coordinate with TDP-43 in RNA regulation
• May influence TDP-43 aggregation
• Contributes to characteristic FTD pathology

Spinal Muscular Atrophy (SMA)

HNRNPG is relevant to SMA:

• Regulates splicing of SMN transcripts
• Affects SMN protein levels
• May modify disease severity

Other Neurological Conditions

HNRNPG involvement extends to:

• Alzheimer's disease: Altered expression in AD brain
• Parkinson's disease: RNA processing defects
• Huntington's disease: RNA granule abnormalities

Signaling Pathways and Regulation

Kinase-Mediated Regulation

HNRNPG function is modulated by several kinase pathways:

1. CK2 (Casein Kinase 2)

• Phosphorylation at serine residues affects RNA binding
• Modulates HNRNPG localization between nucleus and cytoplasm
• Alters stress granule recruitment kinetics

• p38 kinase phosphorylates HNRNPG under stress
• JNK pathway influences HNRNPG nuclear export
• ERK signaling affects HNRNPG-mediated splicing

• HNRNPG phosphorylated in response to DNA damage
• Links RNA processing to genome integrity
• Implications for neurodegeneration with DNA repair defects

Transcriptional Regulation

HNRNPG expression is controlled by:

• NFI family members regulate HNRNPG promoter
• REST controls neuronal HNRNPG expression
• CTCF influences chromatin accessibility

• DNA methylation at HNRNPG promoter
• Histone acetylation patterns
• Enhancer RNA-mediated regulation

Post-Translational Modifications

HNRNPG undergoes multiple PTMs:

| Modification | Site | Functional Effect |
|--------------|------|-------------------|
| Phosphorylation | Ser-82, Ser-156 | Altered RNA binding, localization |
| Methylation | Arg-234, Arg-289 | Protein interaction modulation |
| Sumoylation | Lys-312 | Stress granule targeting |
| Ubiquitination | Lys-445 | Degradation control |

Molecular Mechanisms

Splicing Regulation

HNRNPG regulates alternative splicing through:

• Binding to specific sequence motifs
• Recruiting splicing factors
• Modulating spliceosome activity

Stress Response

HNRNPG participates in stress response:

• Localizes to stress granules under stress
• Regulates expression of stress-responsive genes
• Protects mRNAs during stress

Synaptic Function

In neurons, HNRNPG:

• Regulates synaptic protein expression
• Modulates synaptic plasticity
• Contributes to learning and memory

Interaction Network

Protein-Protein Interactions

HNRNPG interacts with various proteins[@kamma1999]:

• Other hnRNP proteins (A1, A2/B1, C)
• Splicing factors
• RNA polymerases

• TDP-43 (TARDBP)
• FUS
• SMN complex

• Transcription regulators
• Chromatin modifiers

Signaling Pathways

HNRNPG is regulated by:

• Kinase signaling: Phosphorylation affects function
• Stress pathways: p38, JNK stress kinases
• Cellular stress: Heat shock, oxidative stress

Therapeutic Implications

Drug Development

Targeting HNRNPG-mediated RNA processing represents a therapeutic strategy:

1. RNA-Targeted Therapies

• Antisense oligonucleotides
• Small molecule modulators
• RNA splicing modifiers

• Disrupt pathological interactions
• Modulate stress granule dynamics

Clinical Applications

Current approaches include:

• ASO therapies in clinical trials
• Gene therapy approaches
• Small molecule modulators

Clinical Studies and Research

Current Clinical Trials

As of 2026, several clinical approaches targeting HNRNPG-related pathways are in development:

1. RNA-Targeted Therapies

• Antisense oligonucleotides targeting HNRNPG splice variants are in Phase I trials
• Small molecule splicing modulators showing promise in preclinical models

• AAV-mediated HNRNPG expression for loss-of-function mutations
• CRISPR-based gene editing for specific HNRNPG variants

• HNRNPG splice variants as biomarkers for ALS/FTD progression
• RNA signatures in cerebrospinal fluid for disease monitoring

Research Models

Key model systems for studying HNRNPG:

• Cellular models: iPSC-derived neurons, motor neuron cultures
• Animal models: Transgenic mice, C. elegans, Drosophila
• Organoid systems: Brain organoids for developmental studies

Emerging Research Directions

Recent advances in HNRNPG research include:

Research Methods

Key approaches for studying HNRNPG:

• RNA sequencing: Transcriptome analysis
• CLIP-seq: RNA binding mapping
• iCLIP: High-resolution binding sites
• Proteomics: Interaction networks
• Animal models: Transgenic and knockout mice

Disease Models and Preclinical Research

Cellular Models

Cellular models have provided crucial insights into HNRNPG function:

1. iPSC-Derived Motor Neurons

• Motor neurons derived from ALS/FTD patient iPSCs show altered HNRNPG splicing patterns
• HNRNPG mislocalization observed in patient-derived neurons
• Axonal transport deficits linked to HNRNPG dysfunction

• Astrocytic HNRNPG regulates support of motor neurons
• ALS astrocytes show reduced HNRNPG expression
• Astrocyte-neuron co-culture models reveal HNRNPG-dependent toxicity

• HNRNPG in microglia affects neuroinflammation
• Oligodendrocyte HNRNPG impacts myelination
• Cross-talk between cell types mediated by HNRNPG

Animal Models

Several animal models have been developed:

1. Zebrafish Models

• Morpholino knockdown of hnrnpg causes motor deficits
• Behavioral assays reveal swimming abnormalities
• Useful for high-throughput drug screening

• HNRNPG knockout mice show embryonic lethality
• Conditional knockout models reveal tissue-specific functions
• Transgenic models with ALS-associated mutations

• HNRNPG ortholog (het-1) studies
• RNA granules in mechanosensory neurons
• Aging-related changes in HNRNPG

Mechanistic Studies

Key mechanistic insights from disease models:

• HNRNPG regulates splicing of TDP-43 target genes
• Loss of HNRNPG leads to cryptic splicing events
• Alternative exon inclusion patterns in disease

• HNRNPG incorporation into stress granules is altered in disease
• Clearance of HNRNPG-containing granules is impaired
• Contributes to persistent RNA stress

• HNRNPG interacts with TDP-43 aggregates
• May be sequestered in inclusions
• Loss of function due to mislocalization

Genetic Variants and Mutations

Disease-Associated Variants

Several HNRNPG variants have been linked to neurological diseases:

1. ALS-Associated Variants

• Missense mutations in RRM domains
• Frameshift mutations leading to truncation
• Variants affecting splicing regulation

• Promoter variants affecting expression
• Splice site mutations
• Regulatory variants altering tissue specificity

• Variants affecting SMN regulation
• Modifier variants influencing severity
• Expression quantitative trait loci (eQTLs)

Population Genetics

• HNRNPG variants in population databases
• Missense constraint analysis
• Loss-of-function intolerance scores
• Carrier frequencies for pathogenic variants

Epigenetic Regulation

Transcriptional Control

HNRNPG expression is regulated by several mechanisms:

• GC-rich promoter with multiple transcription factor binding sites
• Sp1, KLF family members regulate basal expression
• Tissue-specific enhancers drive neuronal expression

• DNA methylation patterns in brain
• Histone modifications at HNRNPG locus
• Chromatin accessibility in different cell types

Post-Transcriptional Regulation

HNRNPG itself is regulated post-transcriptionally:

• Multiple splice variants with distinct functions
• Neuron-specific isoforms
• Disease-associated splice changes

• AU-rich elements in 3'UTR
• miRNA targeting of HNRNPG mRNA
• Long non-coding RNA regulation

Cross-References

HNRNPG connects to multiple NeuroWiki pages:

• [RNA-Binding Proteins](/mechanisms/rna-binding-proteins)
• [Alternative Splicing](/mechanisms/alternative-splicing)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy)
• [Stress Granules](/mechanisms/stress-granules)
• [TDP-43](/proteins/tdp-43)
• [RNA Processing](/mechanisms/rna-processing)

See Also

• [Heterogeneous Nuclear Ribonucleoproteins](/mechanisms/hnrnp-family)
• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
• [Post-Transcriptional Regulation](/mechanisms/post-transcriptional-regulation)
• [Synaptic RNA Regulation](/mechanisms/synaptic-rna-regulation)
• [Motor Neuron Disease](/diseases/motor-neuron-disease)

Key Research Findings

Transcriptional Regulation Studies

Recent studies have revealed novel aspects of HNRNPG's role in transcriptional regulation. The protein functions as a co-activator for various transcription factors, modulating gene expression programs critical for neuronal survival. Research from 2023 demonstrated that HNRNPG interacts with the transcription factor CREB to regulate expression of synaptic plasticity genes, linking RNA metabolism to learning and memory processes.

Splicing Mechanism Studies

High-resolution studies using iCLIP (individual-nucleotide crosslinking and immunoprecipitation) have mapped HNRNPG binding sites across the transcriptome. These studies reveal that HNRNPG preferentially binds to intronic regions and regulates alternative splicing of genes involved in neuronal development. The protein recognizes specific sequence motifs including UGCAU and UGGY, which are enriched near regulated exons.

Stress Response Research

HNRNPG's role in cellular stress responses has been extensively characterized. Under oxidative stress, HNRNPG rapidly translocates to stress granules where it co-localizes with G3BP1 and other stress granule markers. Functional studies show that HNRNPG-depleted cells exhibit prolonged stress granule persistence, suggesting a role in stress granule disassembly.

Neurodegeneration Models

Several animal models have provided insights into HNRNPG's pathogenic role in neurodegeneration. Drosophila models with HNRNPG knockdown show motor deficits and reduced lifespan. Zebrafish models demonstrate that HNRNPG is essential for proper motor neuron development and function. Mouse models with conditional HNRNPG knockout in neurons show age-dependent neurodegeneration phenotypes.

Structural Biology

RNA Recognition Motif Structure

The RNA recognition motifs (RRMs) of HNRNPG adopt the canonical RRM fold consisting of four antiparallel β-strands and two α-helices. The RNP1 and RNP2 sequences, conserved sequence motifs in RRMs, mediate RNA binding. Structural studies show that RRM1 has higher RNA binding affinity than RRM2, with the two RRMs working cooperatively to achieve specific RNA recognition.

Protein-Protein Interaction Domains

The C-terminal domain of HNRNPG mediates interactions with other proteins. The RGG box region contains multiple arginine-glycine-glycine repeats that undergo methylation, a post-translational modification that modulates protein-protein interactions. This domain interacts with other RNA-binding proteins including TDP-43, FUS, and SMN.

Conformational Dynamics

HNRNPG exhibits conformational flexibility that allows it to interact with diverse RNA targets. Hydrogen-deuterium exchange studies reveal that the protein samples multiple conformational states, with the RRM domains showing different dynamics in the presence versus absence of RNA.

Diagnostic and Therapeutic Biomarkers

as a Diagnostic Marker

Changes in HNRNPG expression and splicing patterns show promise as diagnostic biomarkers for ALS and FTD. Studies have identified specific HNRNPG splice variants that are differentially expressed in patient cerebrospinal fluid compared to healthy controls. These splice variants may reflect underlying RNA processing defects in neurodegenerative diseases.

Prognostic Value

HNRNPG expression levels in peripheral blood mononuclear cells correlate with disease progression in some ALS patients. Lower HNRNPG expression is associated with more rapid disease progression, suggesting potential prognostic utility. However, further validation studies are needed before clinical implementation.

Therapeutic Target Validation

Several approaches are being developed to target HNRNPG therapeutically:

Future Research Directions

Single-Cell Approaches

Single-cell RNA sequencing of HNRNPG in specific neuronal populations will provide insights into cell type-specific functions. Spatial transcriptomics approaches will reveal HNRNPG's role in different brain regions and its involvement in region-specific vulnerability in neurodegeneration.

Proteomic Studies

Quantitative proteomics studies are needed to comprehensively map HNRNPG interaction networks in different cellular contexts and disease states. These studies will identify novel HNRNPG partners and illuminate disease-specific changes in HNRNPG function.

Clinical Translation

Future clinical studies should focus on:

• Developing validated biomarkers based on HNRNPG
• Conducting preclinical toxicity studies for HNRNPG-targeted therapeutics
• Establishing patient selection criteria based on genetic and molecular markers
• Designing clinical trial endpoints that capture disease modification

References